Andrew P. Smith Sells 1,766 Shares of Sucampo Pharmaceuticals Inc. (SCMP) Stock
Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) CFO Andrew P. Smith sold 1,766 shares of Sucampo Pharmaceuticals stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $15.58, for a total value of $27,514.28. Following the sale, the chief financial officer now directly owns 348 shares of the company’s stock, valued at approximately $5,421.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) traded up 1.46% during mid-day trading on Friday, hitting $15.60. The stock had a trading volume of 81,625 shares. The stock has a 50-day moving average price of $12.94 and a 200 day moving average price of $11.89. The firm has a market cap of $667.96 million, a P/E ratio of 52.70 and a beta of 1.62. Sucampo Pharmaceuticals Inc. has a 12-month low of $9.59 and a 12-month high of $18.75.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.02. The firm had revenue of $57.90 million for the quarter, compared to the consensus estimate of $51.30 million. Sucampo Pharmaceuticals had a return on equity of 44.19% and a net margin of 6.29%. The firm’s quarterly revenue was up 73.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.16 EPS. Equities analysts anticipate that Sucampo Pharmaceuticals Inc. will post $1.22 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Globeflex Capital L P boosted its stake in Sucampo Pharmaceuticals by 0.3% in the second quarter. Globeflex Capital L P now owns 23,649 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 61 shares during the last quarter. Smith Asset Management Group LP boosted its stake in Sucampo Pharmaceuticals by 2.1% in the third quarter. Smith Asset Management Group LP now owns 10,950 shares of the biopharmaceutical company’s stock worth $135,000 after buying an additional 220 shares during the last quarter. ProShare Advisors LLC boosted its stake in Sucampo Pharmaceuticals by 1.0% in the second quarter. ProShare Advisors LLC now owns 36,954 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 369 shares during the last quarter. BlackRock Group LTD boosted its stake in Sucampo Pharmaceuticals by 2.0% in the third quarter. BlackRock Group LTD now owns 20,706 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 405 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in Sucampo Pharmaceuticals by 1.6% in the third quarter. Rhumbline Advisers now owns 27,355 shares of the biopharmaceutical company’s stock worth $337,000 after buying an additional 425 shares during the last quarter. Hedge funds and other institutional investors own 41.14% of the company’s stock.
A number of equities research analysts recently commented on the company. Maxim Group lifted their target price on Sucampo Pharmaceuticals from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Tuesday. Mizuho boosted their price target on Sucampo Pharmaceuticals from $13.00 to $16.00 and gave the company a “neutral” rating in a report on Monday. Jefferies Group reissued a “hold” rating and issued a $16.00 price target (up from $14.00) on shares of Sucampo Pharmaceuticals in a report on Friday, November 11th. Vetr downgraded Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $14.00 price target for the company. in a report on Monday, September 19th. Finally, Zacks Investment Research raised Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, August 8th. Five equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Sucampo Pharmaceuticals has an average rating of “Buy” and a consensus target price of $17.33.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.
Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.